A5010192207- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Gene expression and cancer classification
- Genetic factors in colorectal cancer
- Colorectal Cancer Treatments and Studies
- HER2/EGFR in Cancer Research
- Hematological disorders and diagnostics
- Heparin-Induced Thrombocytopenia and Thrombosis
- Hedgehog Signaling Pathway Studies
- Monoclonal and Polyclonal Antibodies Research
- Acute Myeloid Leukemia Research
- Nonmelanoma Skin Cancer Studies
- Inflammatory mediators and NSAID effects
- RNA modifications and cancer
- Chronic Lymphocytic Leukemia Research
- Cancer and Skin Lesions
- Molecular Biology Techniques and Applications
- Ferroptosis and cancer prognosis
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Cerebral Venous Sinus Thrombosis
- Cancer-related Molecular Pathways
- Venous Thromboembolism Diagnosis and Management
Tempus Labs (United States)
2020
Bristol-Myers Squibb (United States)
2016-2017
Center for Drug Evaluation and Research
2013
United States Food and Drug Administration
2013
The University of Texas Southwestern Medical Center
2007-2009
Dallas VA Medical Center
2007
Southwestern Medical Center
2007
University of Michigan–Ann Arbor
1999
The data and regulatory considerations leading to the U.S. Food Drug Administration (FDA) January 30, 2012 approval of Erivedge (vismodegib) capsules for treatment patients with recurrent, locally advanced, or metastatic basal cell carcinoma (BCC) are described. FDA's decision was based primarily on results observed in a single-arm, parallel cohort, international trial vismodegib, administered orally at 150 mg daily until disease progression, pathologically confirmed, advanced (laBCC)...
3501 Background: Evidence supports use of nivolumab (N) in MSI-H mCRC. N, a fully human anti-PD-1 mAb and ipilimumab (I), humanized anti-CTLA-4 mAb, have favorable safety & efficacy other tumors. CheckMate-142, phase 2 study, evaluates N ± I pts with mCRC, non-MSI-H. Methods: Pts had ECOG PS 0–1, intolerance/progression on ≥ 1 tx. received 3 mg/kg q2 wk (N3) or + q3 (N3+I1) x 4 doses followed by N3 until disease progression (PD) discontinuation. Initial evaluation N+I at was completed...
We have reported that HT29 colon cancer cells, which are radiosensitized by fluorodeoxyuridine (FdUrd), exhibit a greater increase in cyclin E—dependent kinase activity and progress further into S phase the presence of FdUrd than do SW620 only minimally sensitized this drug (Cancer Res 56: 3203, 1996). Although these findings suggested ability to permits cells be radiosensitized, we wished test hypothesis attempting drive human transducing them with HPV16-E7 gene. Two-parameter flow...
Abstract INTRODUCTION We performed a retrospective analysis of longitudinal real-world data (RWD) from breast cancer patients to replicate results clinical studies and demonstrate the feasibility generating evidence. also assessed value transcriptome profiling as complementary tool for determining molecular subtypes. PATIENTS AND METHODS De-identified, were analyzed after abstraction U.S. patient records structured stored in Tempus database. Demographics, characteristics, subtype, treatment...